Extrapancreatic effects of sulfonylurea drugs.
Extrapancreatic action of sulfonylurea (SU) drugs were extensively summarized. Hypoglycemic SU drugs stimulate glycolytic pathway and inhibit gluconeogenic pathway in the liver through regulating key enzymes such as the bifunctional enzyme PFK2/F-2,6-P2ase and PEPCK. It is possible that SUs improve the primary defects in NIDDM through both pancreatic and extrapancreatic actions.
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan.
K
K
Kaku
Y
Y
Inoue
T
T
Kaneko
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism; D005943:Gluconeogenesis / Q000187:drug effects; D006019:Glycolysis / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000502:physiology; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008954:Models, Biological; D010732:Phosphofructokinase-1 / Q000378:metabolism; D025481:Phosphofructokinase-2; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D014044:Tolbutamide / Q000494:pharmacology
D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D014044:Tolbutamide; D025481:Phosphofructokinase-2; D010732:Phosphofructokinase-1; D010744:Phosphoric Monoester Hydrolases